United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

27 Oct 2016
Change (% chg)

¥-16 (-0.33%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical, Altos Therapeutics to develop Altos's ATC-1906
Friday, 1 Jul 2016 08:00am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Co, Altos Therapeutics have entered into agreement to further development of Altos's proprietary compound ATC-1906 . Deal has option for co to acquire Altos from date of agreement, continuing for some time after completion of Phase 1 studies of ATC-1906 . As part of agreement, Takeda will provide Altos an upfront payment for option to acquire Altos . If Takeda elects to exercise option to buy Altos, Takeda would make an additional payment to acquire Altos . Altos would be eligible to receive additional payments linked to clinical development and achievement of key commercial milestones .No further details of agreement were disclosed.  Full Article

Takeda licenses global rights to Theravance Biopharma's TD-8954
Wednesday, 8 Jun 2016 08:00am EDT 

Theravance Biopharma Inc : Takeda Licenses Global Rights To Theravance Biopharma's Td-8954, a novel 5-HT4 agonist and motility agent for gastrointestinal motility disorders . Theravance biopharma inc says will receive an upfront cash payment of $15 million .Will be eligible to receive success based development and sales milestone payments as well as double digit royalties on worldwide net sales by takeda.  Full Article

Ultragenyx, Takeda enter into collaboration to develop, commercialize therapies for rare genetic diseases
Tuesday, 7 Jun 2016 07:00am EDT 

Ultragenyx Pharmaceutical Inc : Ultragenyx and Takeda enter into a collaboration to develop and commercialize therapies for rare genetic diseases . Ultragenyx pharmaceutical inc says to license and develop one or more product candidates from Takeda . Ultragenyx pharmaceutical inc says Takeda to make equity investment in Ultragenyx to fund development . Ultragenyx pharmaceutical inc says Takeda will invest up to $65 million in Ultragenyx in two tranches . A potential third equity investment by Takeda is contingent upon Ultragenyx achieving a specific development milestone on a second asset .Ultragenyx Pharmaceutical Inc says no additional financial details were disclosed.  Full Article

Takeda, Roivant Sciences launch Myovant Sciences to develop therapeutics for women's health, prostate cancer
Monday, 6 Jun 2016 07:00am EDT 

Takeda Pharmaceutical Co <4502.T>: Roivant Sciences and Takeda launch Myovant Sciences to develop therapeutics for women's health and prostate cancer .Lynn Seely named president & Chief Executive Officer of Myovant Sciences Inc.  Full Article

EU health agency recommends approval of new hepatitis C drugs
Friday, 27 May 2016 07:21am EDT 

EU Medicines Agency : EU Medicines Agency recommendations for May 2016 . Recommends against approval of Takeda Pharmaceutical Co Ltd's <4502.T> ixazomib to treat multiple myeloma . Recommends approval of AstraZeneca Plc's saxagliptin/dapagliflozin to treat type 2 diabetes . Recommends approval of Takeda Pharmaceutical Co Ltd and Janssen's bortezomib to treat multiple myeloma . Recommends approval of Gilead Sciences Inc's sofosbuvir/velpatasvir to treat Hepatitis C .Recommends approval of Merck & Co's Elbasvir / grazoprevir to treat Hepatitis C.  Full Article

Valeant received joint takeover approach from Takeda, TPG before Joseph Papa became CEO - source
Thursday, 26 May 2016 11:00pm EDT 

: Valeant received joint takeover approach from Takeda, TPG a few weeks before Joseph Papa became CEO - Source Further company coverage: [VRX.TO] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Valeant approached by earlier rejected Takeda, TPG for takeover-CNBC
Thursday, 26 May 2016 07:22pm EDT 

: Valeant received joint takeover approach from Takeda, TPG that it rejected this spring before hiring new CEO - CNBC, citing DJ .There are no current talks between Takeda, TPG And Valeant following rejection of takeover bid this spring - CNBC, citing DJ.  Full Article

Takeda Pharmaceutical and Orexigen Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in United States
Tuesday, 15 Mar 2016 07:00pm EDT 

Takeda Pharmaceutical Co Ltd:Orexigen Therapeutics, Inc. and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda”), announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE®.CONTRAVE® (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management.Orexigen and Takeda are committed to working together to ensure a successful transition of development and commercialization efforts for CONTRAVE.Following closing of this transaction, the parties have agreed to a 180-day transition period, during which time Takeda will continue to commercialize CONTRAVE in the United States.  Full Article

ASKA Pharmaceutical signs commercialization contract for treatment of hypertension with Takeda Pharmaceutical
Wednesday, 24 Feb 2016 01:00am EST 

ASKA Pharmaceutical Co Ltd:Says signed commercialization contract for a treatment of hypertension with Takeda Pharmaceutical on Feb. 24.Says ASKA Pharmaceutical obtain manufacturing and marketing approval for the treatment of hypertension from the Ministry of Health, Labour and Welfare in February.  Full Article

Takeda Pharmaceutical to establish subsidiary
Wednesday, 3 Feb 2016 01:00am EST 

Takeda Pharmaceutical Co Ltd:To establish a wholly owned subsidiary based in Osaka in April.New subsidiary to be engaged in production and sale of pharmaceuticals, quasi-drugs, medical equipment.New subsidiary to be capitalized at 10 million yen.  Full Article